The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; CareNet; Chugai Pharma; Covidien; Johnson & Johnson; Lilly Japan; Mochida Pharmaceutical Co. Ltd.; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Randomized phase III study of irinotecan/cisplatin (IP) versus etoposide/cisplatin (EP) for completely resected high-grade neuroendocrine carcinoma (HGNEC) of the lung: JCOG1205/1206.
 
Hirotsugu Kenmotsu
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst)
 
Seiji Niho
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD; Novartis; Pfizer; Shionogi; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Pfizer (Inst)
 
Masahiro Tsuboi
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Johnson & Johnson; Medtronic; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Research Funding - Boehringer Ingelheim (Inst); Merck (Inst)
 
Masashi Wakabayashi
Honoraria - Chugai Pharma; Johnson & Johnson
 
Genichiro Ishii
No Relationships to Disclose
 
Kazuo Nakagawa
No Relationships to Disclose
 
Haruko Daga
Honoraria - Chugai/Roche; MSD Oncology; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai/Roche (Inst); Lilly (Inst)
 
Hiroshi Tanaka
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD Oncology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Haruhiro Saito
Honoraria - Bristol-Myers Squibb Japan; Nippon Boehringer Ingelheim; Novar Pharma; Ono Pharmaceutical
Patents, Royalties, Other Intellectual Property - AstraZeneca (Inst); Chugai Pharma (Inst)
 
Keiju Aokage
No Relationships to Disclose
 
Toshiaki Takahashi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly; Merck Sharp & Dohme; Ono Pharmaceutical; Pfizer; Roche
Research Funding - AstraZeneca Japan (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Toshi Menju
No Relationships to Disclose
 
Takashi Kasai
Honoraria - AstraZeneca Japan; AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly; Merck Sharp & Dohme; Merck Sharp & Dohme; Ono Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Ichiro Yoshino
No Relationships to Disclose
 
Koichi Minato
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; MSD K.K
Research Funding - Bristol-Myers Squibb Japan (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Morihito Okada
Speakers' Bureau - AstraZeneca; Chugai Pharma; Covidien; CSL Behring; Johnson & Johnson; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Johnson & Johnson (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nihon Medi-Physics (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Hiroshi Katayama
No Relationships to Disclose
 
Hisao Asamura
No Relationships to Disclose
 
Yuichiro Ohe
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Kyorin; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Celltrion; Chugai Pharma; Kyorin; Lilly Japan; Novartis; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Ignyta (Inst); Janssen (Inst); Kissei Pharmaceutical (Inst); Kyorin (Inst); Lilly Japan (Inst); LOXO (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Shun-ichi Watanabe
No Relationships to Disclose